AI in SK Histopathological Diagnosis (AI\SK)

August 23, 2026 updated by: Hebatullah Fouad Mahmoud Elkerm, Al-Azhar University

Evaluation of Artificial Intelligence Algorithms Performance in the Histopathological Diagnosis of Seborrheic Keratosis

The aim of this study is to evaluate the diagnostic performance of an Artificial Intelligence (AI) algorithm in the histopathological diagnosis of Seborrheic keratosis compared to Certified Dermatopathologists.

Study Overview

Status

Not yet recruiting

Detailed Description

Seborrheic keratosis (SK) is one of the most common benign epidermal tumors. Treatment is generally unnecessary, although lesions may be removed because of irritation, pruritus, or cosmetic concerns. SK has several clinical and histological subtypes, including common seborrheic keratosis (CSK), which is more prevalent among Caucasians, and dermatosis papulosa nigra (DPN), which is more common in individuals with Fitzpatrick skin phototypes III and above. Its development is associated mainly with age and genetic predisposition, with possible contribution from ultraviolet radiation. Lesions may occur almost anywhere except the palms and soles, with the face and upper trunk being common sites. Diagnosis is usually clinical but may be supported by dermoscopy or histopathology.

Histologically, SK represents an intraepidermal proliferation of squamous or basaloid cells. The characteristic findings include acanthosis, papillomatosis, hyperkeratosis, keratin cysts, and keratin pseudocysts. Cellular atypia is generally absent, while the amount of melanin and melanocytes varies according to the degree of pigmentation. SK shows considerable clinical and histological variability, which can sometimes make differentiation from other lesions, such as keratoacanthoma and clear cell acanthoma, challenging.

Recent advances in digital pathology and artificial intelligence (AI) have created new opportunities for diagnostic support in dermatopathology. AI aims to mimic aspects of human intelligence, while machine learning enables computers to identify patterns from data. Deep learning, neural networks, and convolutional neural networks (CNNs) are particularly important in image analysis. AI in dermatopathology has evolved from early text-based systems such as TEGUMENT, introduced in 1987, to modern systems capable of directly analyzing digital pathology images. Although widespread clinical implementation is still developing, AI has potential applications in diagnosis, triage, education, and research and requires collaboration between dermatopathologists, pathologists, clinicians, engineers, and data scientists.

Study Methodology

H&E-stained glass slides will be collected from the Al-Hussein dermatopathology archive, covering the period from 2010 to 2019. A panel of certified dermatopathologists will evaluate the slides. Their diagnoses will serve as the gold standard against which the AI results will be compared.

The slides will be digitized using a Leica Aperio GT450 scanner at 40× magnification. Before scanning, slides will be cleaned and assessed for adequate staining, proper coverslipping, and absence of artifacts such as air bubbles, tissue folds, or debris. The scanner can accommodate 15 racks with 30 slides per rack, for a total of 450 slides per run, with approximately 1.5-2 minutes required to scan each slide.

Whole Slide Images (WSIs) will be generated and stored in SVS format, with individual file sizes typically ranging from approximately 500 MB to 2 GB. The digital slides will then undergo quality control using Aperio ImageScope to ensure adequate focus, clarity, and complete tissue capture. Suboptimal slides will be rescanned. The images will subsequently be transferred to an external hard drive for storage and backup before being uploaded to the HistoGPT cloud platform for AI analysis.

HistoGPT Analysis

The WSIs will be analyzed using HistoGPT, a Vision-Language Model for Digital Pathology. Because WSIs are extremely large, they are first divided into smaller image patches or tiles, typically 256×256 or 512×512 pixels. Tissue detection is then performed to exclude background areas and focus the analysis on the tissue.

HistoGPT uses a Vision Transformer (ViT) and a Hierarchical Vision Transformer (HiViT) to extract histological features at multiple scales. This allows the model to identify both microscopic features, such as cellular atypia and mitotic figures, and larger architectural patterns, such as symmetry, circumscription, and infiltrative growth.

Through attention mechanisms, the model can also establish relationships between spatially distant areas of the slide and recognize the importance of tissue organization and anatomical location. Its cross-modal alignment allows visual histological features to be associated with terminology used in pathology reports, enabling recognition of concepts such as keratin pearls, clefting, and solar elastosis.

Finally, the language component of HistoGPT generates a structured pathology report, potentially including a microscopic description, differential diagnosis, and final diagnosis. The AI-generated reports will be compared with the reports and diagnoses produced by the dermatopathology experts, and the time required for the diagnostic process will also be assessed.

Statistical Analysis

The collected data will be analyzed using SPSS version 26.0 or R programming. A p-value < 0.05 will be considered statistically significant. Overall, the study aims to evaluate the diagnostic performance and time efficiency of HistoGPT in dermatopathology by comparing its findings with expert dermatopathologists serving as the gold standard.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Cairo, Egypt
        • Faculty of medicine, Al-Azhar University boys branch in Cairo
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Seborrheic keratosis H&E stained glass slides from the pathology archive of Al-hussein dermatopathology unit.

Description

Inclusion Criteria:

  1. Histopathological slides diagnosed as Seborrheic keratosis.
  2. Slides with adequate staining and preservation allowing clear visualization of histopathological features.

Exclusion Criteria:

  1. Slides with poor staining quality or significant artifacts interfering with histopathological interpretation.
  2. Slides that were damaged, faded, or inadequately preserved.
  3. Cases with uncertain or inconclusive original diagnoses.
  4. Slides that could not be successfully digitized due to technical limitations ex: very short or too long slides.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The accuracy of the artificial intelligence algorithm in histopathological diagnosis of seborrheic keratosis evaluated mainly by sensitivity and specificity.
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

August 23, 2026

First Submitted That Met QC Criteria

August 23, 2026

First Posted (Actual)

August 26, 2026

Study Record Updates

Last Update Posted (Actual)

August 26, 2026

Last Update Submitted That Met QC Criteria

August 23, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 303 (Klein Buendel, Inc.)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe